WO1999055305A3 - Compositions de levosimendane perorales a liberation controlee - Google Patents

Compositions de levosimendane perorales a liberation controlee Download PDF

Info

Publication number
WO1999055305A3
WO1999055305A3 PCT/FI1999/000329 FI9900329W WO9955305A3 WO 1999055305 A3 WO1999055305 A3 WO 1999055305A3 FI 9900329 W FI9900329 W FI 9900329W WO 9955305 A3 WO9955305 A3 WO 9955305A3
Authority
WO
WIPO (PCT)
Prior art keywords
levosimendan
controlled release
peroral compositions
release peroral
compositions
Prior art date
Application number
PCT/FI1999/000329
Other languages
English (en)
Other versions
WO1999055305A2 (fr
Inventor
Ilkka Larma
Maarit Harjula
Saila Antila
Lasse Lehtonen
Original Assignee
Orion Corp
Ilkka Larma
Maarit Harjula
Saila Antila
Lasse Lehtonen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8551575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1999055305(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to PL344078A priority Critical patent/PL197447B1/pl
Priority to KR1020007011788A priority patent/KR100960597B1/ko
Priority to SI9930536T priority patent/SI1071397T1/xx
Priority to JP2000545505A priority patent/JP4566402B2/ja
Priority to US09/673,794 priority patent/US7045147B1/en
Priority to AT99916941T priority patent/ATE258425T1/de
Priority to CA002329234A priority patent/CA2329234C/fr
Priority to EA200001098A priority patent/EA002829B1/ru
Priority to HU0101458A priority patent/HUP0101458A3/hu
Priority to EP99916941A priority patent/EP1071397B1/fr
Priority to SK1554-2000A priority patent/SK285427B6/sk
Priority to MXPA00010367A priority patent/MXPA00010367A/es
Priority to NZ507453A priority patent/NZ507453A/xx
Priority to DK99916941T priority patent/DK1071397T3/da
Application filed by Orion Corp, Ilkka Larma, Maarit Harjula, Saila Antila, Lasse Lehtonen filed Critical Orion Corp
Priority to EEP200000617A priority patent/EE04220B1/xx
Priority to BR9909869-5A priority patent/BR9909869A/pt
Priority to IL13895199A priority patent/IL138951A0/xx
Priority to AU35246/99A priority patent/AU756641B2/en
Priority to UA2000116616A priority patent/UA68376C2/uk
Priority to DE69914472T priority patent/DE69914472T2/de
Publication of WO1999055305A2 publication Critical patent/WO1999055305A2/fr
Publication of WO1999055305A3 publication Critical patent/WO1999055305A3/fr
Priority to IL138951A priority patent/IL138951A/en
Priority to HR20000704A priority patent/HRP20000704B1/xx
Priority to NO20005313A priority patent/NO329809B1/no
Priority to HK01101050A priority patent/HK1034032A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques perorales qui libèrent le lévosimendane de façon contrôlée avec peu d'effets indésirables. Le lévosimendane, ou (-)-[[4-(1,4,5,6-tétrahydro-4-méthyl-6-oxo-3-pyridazinyl)phényl]-hydrazono]propanedinitrile, est utile pour le traitement de l'insuffisance cardiaque congestive.
PCT/FI1999/000329 1998-04-23 1999-04-23 Compositions de levosimendane perorales a liberation controlee WO1999055305A2 (fr)

Priority Applications (24)

Application Number Priority Date Filing Date Title
KR1020007011788A KR100960597B1 (ko) 1998-04-23 1999-04-23 레보시멘단의 조절 방출성 경구 조성물
DK99916941T DK1071397T3 (da) 1998-04-23 1999-04-23 Levosimendan-holdige lægemidler til oral indgivelse med kontrolleret frisætning af det aktive middel
NZ507453A NZ507453A (en) 1998-04-23 1999-04-23 Oral sustained release compositions of levosimendan with a hydrophilic gel forming polymer
JP2000545505A JP4566402B2 (ja) 1998-04-23 1999-04-23 レボシメンダンの制御放出経口用組成物
US09/673,794 US7045147B1 (en) 1998-04-23 1999-04-23 Controlled release peroral compositions of levosimendan
AT99916941T ATE258425T1 (de) 1998-04-23 1999-04-23 Levosimendanhaltige oral anzuwendende arzneimittel mit gesteuerter wirkstoffverabreichung
CA002329234A CA2329234C (fr) 1998-04-23 1999-04-23 Compositions de levosimendane perorales a liberation controlee
EA200001098A EA002829B1 (ru) 1998-04-23 1999-04-23 Пероральные композиции с контролируемым высвобождением левозимендана
HU0101458A HUP0101458A3 (en) 1998-04-23 1999-04-23 Controlled release peroral compositions of levosimendan
EP99916941A EP1071397B1 (fr) 1998-04-23 1999-04-23 Compositions de levosimendane perorales a liberation controlee
SK1554-2000A SK285427B6 (sk) 1998-04-23 1999-04-23 Prostriedky na orálne podanie s riadeným uvoľňovaním levosimendanu
MXPA00010367A MXPA00010367A (es) 1998-04-23 1999-04-23 Composiciones de levosimendan perorales de liberacion controlada.
SI9930536T SI1071397T1 (en) 1998-04-23 1999-04-23 Controlled release peroral compositions of levosimendan
PL344078A PL197447B1 (pl) 1998-04-23 1999-04-23 Kompozycje lewosimendanu o kontrolowanym uwalnianiu do podawania doustnego
DE69914472T DE69914472T2 (de) 1998-04-23 1999-04-23 Levosimendanhaltige oral anzuwendende arzneimittel mit gesteuerter wirkstoffverabreichung
EEP200000617A EE04220B1 (et) 1998-04-23 1999-04-23 Kontrollitud vabanemisega levosimendani peroraalsed koostised
BR9909869-5A BR9909869A (pt) 1998-04-23 1999-04-23 Composições perorais de liberação controlada de levosimendan
IL13895199A IL138951A0 (en) 1998-04-23 1999-04-23 Controlled release peroral compositions of levosimendan
AU35246/99A AU756641B2 (en) 1998-04-23 1999-04-23 Controlled release peroral compositions of levosimendan
UA2000116616A UA68376C2 (en) 1998-04-23 1999-04-23 Peroral pharmaceutical composition with controlled release of levosimendan (variants)
IL138951A IL138951A (en) 1998-04-23 2000-10-11 Controlled release of Froel Malbusmandan
HR20000704A HRP20000704B1 (en) 1998-04-23 2000-10-19 Controlled release peroral compositions of levosimendan
NO20005313A NO329809B1 (no) 1998-04-23 2000-10-20 Perorale sammensetninger av levosimendan med kontrollert frigjoring
HK01101050A HK1034032A1 (en) 1998-04-23 2001-02-14 Controlled release peroral compositions of levosimendan

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI980901A FI980901A (fi) 1998-04-23 1998-04-23 Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
FI980901 1998-04-23

Publications (2)

Publication Number Publication Date
WO1999055305A2 WO1999055305A2 (fr) 1999-11-04
WO1999055305A3 true WO1999055305A3 (fr) 1999-12-29

Family

ID=8551575

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI1999/000329 WO1999055305A2 (fr) 1998-04-23 1999-04-23 Compositions de levosimendane perorales a liberation controlee

Country Status (38)

Country Link
US (1) US7045147B1 (fr)
EP (1) EP1071397B1 (fr)
JP (2) JP4566402B2 (fr)
KR (1) KR100960597B1 (fr)
CN (1) CN1248691C (fr)
AR (1) AR019096A1 (fr)
AT (1) ATE258425T1 (fr)
AU (1) AU756641B2 (fr)
BG (1) BG64839B1 (fr)
BR (1) BR9909869A (fr)
CA (1) CA2329234C (fr)
CO (1) CO5070607A1 (fr)
CZ (1) CZ295194B6 (fr)
DE (1) DE69914472T2 (fr)
DK (1) DK1071397T3 (fr)
EA (1) EA002829B1 (fr)
EE (1) EE04220B1 (fr)
ES (1) ES2215379T3 (fr)
FI (1) FI980901A (fr)
GE (1) GEP20032906B (fr)
HK (1) HK1034032A1 (fr)
HR (1) HRP20000704B1 (fr)
HU (1) HUP0101458A3 (fr)
ID (1) ID27987A (fr)
IL (2) IL138951A0 (fr)
MX (1) MXPA00010367A (fr)
NO (1) NO329809B1 (fr)
NZ (1) NZ507453A (fr)
PL (1) PL197447B1 (fr)
PT (1) PT1071397E (fr)
RS (1) RS49962B (fr)
SI (1) SI1071397T1 (fr)
SK (1) SK285427B6 (fr)
TR (1) TR200003102T2 (fr)
TW (1) TWI224507B (fr)
UA (1) UA68376C2 (fr)
WO (1) WO1999055305A2 (fr)
ZA (1) ZA200005632B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20011465A0 (fi) * 2001-07-04 2001-07-04 Orion Corp Pyridatsinonijohdannaisen uusi käyttö
WO2004082615A2 (fr) * 2003-03-14 2004-09-30 Nirmal Mulye Procede de preparation de comprimes a liberation prolongee
FI20070521L (fi) * 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
AU2009267052B2 (en) 2008-06-30 2013-07-11 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
JP2014172850A (ja) * 2013-03-07 2014-09-22 Capsugel Belgium Nv ハードカプセル製剤
CN105784895B (zh) * 2015-10-30 2018-05-22 成都欣捷高新技术开发有限公司 一种用高效液相色谱仪检测左西孟旦中杂质的方法
CA3161960A1 (fr) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan pour traiter l'hypertension pulmonaire accompagnee d'une insuffisance cardiaque au moyen d'une fraction d'ejection preservee (ph-hfpef)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0383449A2 (fr) * 1989-02-11 1990-08-22 Orion-Yhtymà„ Oy Dérivés de pyridazinone et procédé de préparation
WO1992012135A1 (fr) * 1991-01-03 1992-07-23 Orion-Yhtymä Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono]propanedinitrile
WO1993021921A1 (fr) * 1992-05-06 1993-11-11 Orion-Yhtymä Oy Medicament contre l'ischemie
WO1999016443A1 (fr) * 1997-09-26 1999-04-08 Orion Corporation Compositions orales de levosimendan

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU555304B2 (en) 1982-04-05 1986-09-18 Merck Sharp & Dohme Limited Stabilization of drugs in alginic acid and magnesium hydroxide granules
US4716042A (en) 1986-06-16 1987-12-29 American Home Products Corporation Stabilized coated aspirin tablets
US5213811A (en) * 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
GB9614098D0 (en) * 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
FI974578A (fi) * 1997-12-19 1999-06-20 Orion Yhtymae Oyj Menetelmä levosimendaanin antamiseksi
FI980902A (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaanin stabiileja koostumuksia

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0383449A2 (fr) * 1989-02-11 1990-08-22 Orion-Yhtymà„ Oy Dérivés de pyridazinone et procédé de préparation
WO1992012135A1 (fr) * 1991-01-03 1992-07-23 Orion-Yhtymä Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono]propanedinitrile
WO1993021921A1 (fr) * 1992-05-06 1993-11-11 Orion-Yhtymä Oy Medicament contre l'ischemie
WO1999016443A1 (fr) * 1997-09-26 1999-04-08 Orion Corporation Compositions orales de levosimendan

Also Published As

Publication number Publication date
GEP20032906B (en) 2003-02-25
HRP20000704B1 (en) 2009-11-30
TWI224507B (en) 2004-12-01
YU63900A (sh) 2003-07-07
BG104959A (en) 2001-07-31
HUP0101458A3 (en) 2002-05-28
JP2002512946A (ja) 2002-05-08
NZ507453A (en) 2003-02-28
US7045147B1 (en) 2006-05-16
FI980901A (fi) 1999-10-24
EA200001098A1 (ru) 2001-04-23
ZA200005632B (en) 2002-01-14
PL344078A1 (en) 2001-09-24
KR100960597B1 (ko) 2010-06-07
NO20005313L (no) 2000-11-21
SK15542000A3 (sk) 2001-08-06
HUP0101458A2 (hu) 2002-03-28
ID27987A (id) 2001-05-03
TR200003102T2 (tr) 2001-02-21
MXPA00010367A (es) 2002-06-04
PT1071397E (pt) 2004-06-30
KR20010071172A (ko) 2001-07-28
PL197447B1 (pl) 2008-03-31
WO1999055305A2 (fr) 1999-11-04
DK1071397T3 (da) 2004-04-05
JP4566402B2 (ja) 2010-10-20
NO329809B1 (no) 2010-12-20
CZ295194B6 (cs) 2005-06-15
HK1034032A1 (en) 2001-10-12
ATE258425T1 (de) 2004-02-15
BG64839B1 (bg) 2006-06-30
EP1071397A2 (fr) 2001-01-31
CO5070607A1 (es) 2001-08-28
JP2010083900A (ja) 2010-04-15
UA68376C2 (en) 2004-08-16
IL138951A (en) 2006-10-31
CN1301163A (zh) 2001-06-27
CA2329234C (fr) 2008-06-10
CA2329234A1 (fr) 1999-11-04
HRP20000704A2 (en) 2001-04-30
SI1071397T1 (en) 2004-06-30
BR9909869A (pt) 2000-12-19
ES2215379T3 (es) 2004-10-01
EP1071397B1 (fr) 2004-01-28
DE69914472T2 (de) 2004-11-11
RS49962B (sr) 2008-09-29
EA002829B1 (ru) 2002-10-31
EE200000617A (et) 2002-06-17
AU756641B2 (en) 2003-01-16
EE04220B1 (et) 2004-02-16
IL138951A0 (en) 2001-11-25
CN1248691C (zh) 2006-04-05
FI980901A0 (fi) 1998-04-23
SK285427B6 (sk) 2007-01-04
NO20005313D0 (no) 2000-10-20
AU3524699A (en) 1999-11-16
CZ20003780A3 (en) 2001-05-16
DE69914472D1 (de) 2004-03-04
AR019096A1 (es) 2001-12-26

Similar Documents

Publication Publication Date Title
CA2134972A1 (fr) Medicament contre l'ischemie
EE02946B1 (et) (-)-[[4-(1,4,5,6-tetrahüdro-4-metüül-6-okso-3-püridasinüül)fenüül]-hüdrasono]propaan dinitriil, selle valmistamismeetod, soolad, kompositsioonid, vaheühendid ja kasutamine
WO1999055305A3 (fr) Compositions de levosimendane perorales a liberation controlee
WO1999066912A3 (fr) Traitement de l'hypertension arterielle pulmonaire
CA2376930A1 (fr) Methode de traitement ou de prevention du spasme vasculaire resultant d'un pontage aortocoronarien par greffe
CA2412213A1 (fr) Procede pour traiter le choc septique
CA2387920A1 (fr) Nouvelle utilisation du levosimendane
WO2002047603A3 (fr) Methode de traitement de la dyserection
EP1400520A4 (fr) Cristal de trihydrate d'hydrochlorure de 6- 4-(4-pyridylamino)phenyl -4,5-dihydro-3(2h)-pyridazinone

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-639/00

Country of ref document: YU

Ref document number: 99806418.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 35246/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 138951

Country of ref document: IL

Ref document number: 507453

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PV2000-3780

Country of ref document: CZ

Ref document number: 2000/05632

Country of ref document: ZA

Ref document number: 200005632

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 15542000

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2329234

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: P20000704A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/010367

Country of ref document: MX

Ref document number: 1020007011788

Country of ref document: KR

Ref document number: 2000/03102

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2000/432/KOL

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1999916941

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200001098

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 09673794

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999916941

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2000-3780

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007011788

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 35246/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999916941

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: PV2000-3780

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: 1020007011788

Country of ref document: KR